Lack of effect of genetic polymorphisms of SLCO1B1 on the lipid-lowering response to pitavastatin in Chinese patients
Authors:
- 8 February 2010
- journal article
- clinical trial
- Published by Springer Nature in Acta Pharmacologica Sinica
- Vol. 31 (3) , 382-386
Abstract
Aim: Methods: Results: Conclusion:Keywords
This publication has 27 references indexed in Scilit:
- SLCO1B1Variants and Statin-Induced Myopathy — A Genomewide StudyNew England Journal of Medicine, 2008
- The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15Pharmacogenetics and Genomics, 2008
- Organic anion transporting polypeptide-1B1 haplotypes in Chinese patientsActa Pharmacologica Sinica, 2007
- SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acidPharmacogenetics and Genomics, 2006
- Pharmacogenetic determinants of variability in lipid-lowering response to pravastatin therapyJournal of Human Genetics, 2006
- Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environmentClinical Pharmacology & Therapeutics, 2005
- An association study of 43 SNPs in 16 candidate genes with atorvastatin responseThe Pharmacogenomics Journal, 2005
- Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1)British Journal of Clinical Pharmacology, 2005
- Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: similarities and difference in the metabolism of pitavastatin in monkeys and humansXenobiotica, 2003
- Polymorphisms in OATP-CJournal of Biological Chemistry, 2001